Extrait

The primary objectives of this study are: • To estimate the efficacy endpoints of: 1) ORR (confirmed complete response [CR] or confirmed PR), and 2) rate of 6-month PFS (PFS6) of XL147 in relation to the presence or absence of tumor PI3K pathway alterations (ie, molecular alterations that directly affect the PI3K pathway: PIK3CA mutation/amplification and/or PTEN deficiency) in subjects with advanced or recurrent EC • To evaluate the safety and tolerability of XL147 in this population

Critère d'inclusion

• The purpose of this study is to assess the efficacy and safety of XL147 in subjects with Advanced or Recurrent Endometrial Carcinoma

Liens

• ictrp
• ictrp
• euctr
• euctr